RespireRx Pharmaceuticals (RSPI) 10-Q2009 Q1 Quarterly report

Filed: 15 May 09, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: accretion, adequate, ADHD, adult, Alberta, amortization, amortized, announced, apnea, appointment, April, Attention, cease, conserve, convertible, coverage, curtail, deficit, Disorder, doubt, Dr, economy, efficacy, eliminate, explore, exploring, expressed, facilitate, factor, family, firm, flow, forecast, formulation, hierarchy, high, hospital, Hyperactivity, identical, identification, IIb, illiquid, industry, investor, judged, low, maturity, Merck, merge, merger, metabolic, method, negotiate, newly, onset, ownership, past, patent, pharmacokinetic, pilot, platform, potent, preferred, President, previously, protection, public, pursuing, quoted, readied, recently, recruiting, relinquish, safer, salary, served, shown, shut, sleep, solubility, stability, tax, University, vary, water, workforce

Removed: accredited, acknowledgement, arrive, equipment, foregoing, IIa, importantly, Indexed, issuing, MCI, million, molecule, pronouncement, resale, Settled, short, staffing, supplement, termed, tested

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

RSPI similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32

Certification Pursuant to Rule 13a-14(b)/15d-14(b) of the Securities Exchange Act of 1934

and 18 U.S.C. Section 1350

Mark A. Varney, Ph.D., President and Chief Executive Officer of Cortex Pharmaceuticals, Inc. (the “Company”), and Maria S. Messinger, Chief Financial Officer of the Company, each certifies, pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350, that:

(1)	the Quarterly Report on Form 10-Q of the Company for the quarterly period ended March 31, 2009 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 780(d)); and

(2)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Dated: May 15, 2009				/s/ Mark A. Varney
				Mark A. Varney, Ph.D.
				President and Chief Executive Officer

Dated: May 15, 2009				/s/ Maria S. Messinger
				Maria S. Messinger
				Vice President, Chief Financial Officer and Secretary

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.